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Abstract	  	  	  Blood	  cells	  are	  organized	  as	  a	  hierarchy	  with	  haematopoietic	  stem	  cells	  (HSCs)	  at	  its	   root.	   The	   advent	   of	   genomic	   technologies	   has	   opened	   the	   way	   for	   global	  characterization	   of	   the	   molecular	   landscape	   of	   haematopoietic	   stem	   cells	   and	  their	  progeny	  both	   in	  mouse	  and	  human	  models	  at	   the	  genetic,	   transcriptomic,	  epigenetic	  and	  proteomics	   level.	  Here	  we	  outline	  our	  current	  understanding	  of	  the	  molecular	  programmes	  that	  govern	  human	  HSCs	  and	  how	  dynamic	  changes	  occurring	   during	   HSC	   differentiation	   are	   necessary	   for	   well-­‐regulated	   blood	  formation	   under	   homeostasis	   and	   upon	   injury.	   A	   large	   body	   of	   evidence	   is	  accumulating	  on	  how	  these	  programmes	  of	  normal	  haematopoiesis	  are	  modified	  in	   acute	   myeloid	   leukemia	   (AML),	   an	   aggressive	   adult	   malignancy,	   driven	   by	  leukemic	  stem	  cells	  (LSCs).	  Here	  we	  summarise	  these	  findings	  and	  their	  clinical	  implications.	  	  	  	   	  
Introduction	  	  Haematopoietic	   Stem	   Cells	   (HSC)	   exist	   at	   the	   apex	   of	   a	   highly	   coordinated	  hierarchy	  of	  blood	  cells.	  They	  are	  the	  only	  blood	  cells	  that	  possess	  self-­‐renewal,	  the	  ability	  to	  produce	  more	  of	  themselves,	  as	  well	  as	  multipotency,	  the	  capacity	  to	   differentiate	   into	   all	   cell	   types	   of	   the	   blood.	   Another	   important	   property	   of	  HSCs	   is	   their	  quiescence:	   they	  mostly	   reside	  outside	  of	   the	   cell	   cycle	   in	  G0	   and	  divide	   very	   infrequently1–3.	   Quiescence	   is	   actively	   regulated	   intrinsically	   and	  extrinsically	   4,	   and	   is	   thought	   to	   protect	   HSC	   from	   exhaustion	   and	   prevent	  accumulation	  of	  mutations	  with	  malignant	  potential.	  HSC	  are	  also	  characterised	  by	  a	  unique	  metabolic	  programme	  5	  and	  their	  activity	  is	  fine-­‐tuned	  by	  interaction	  with	  their	  microenvironment,	  the	  so-­‐called	  HSC	  niche6	  .	  	  To	   date,	   almost	   all	   of	   our	   understanding	   and	   characterisation	   of	   HSC,	   at	   the	  functional	   and	   phenotypic	   level,	   are	   derived	   from	  mouse	  models,	   but	   detailed	  studies	   of	   human	   HSC	   (hHSC)	   are	   starting	   to	   emerge.	   Because	   of	   the	   slow	  development	   of	   robust	   functional	   assays	   to	   test	   for	   hHSC	   and	   progenitor	  function,	   isolation	   strategies	   of	   these	   cells	   have	   lagged	   behind	   their	   mouse	  counterparts	  (reviewed	  in	  7).	  	  However	  the	  past	  decade	  has	  brought	  a	  number	  of	  novel	   tools	   that	   have	   allowed	   mapping	   the	   precise	   cellular	   roadmap	   of	   hHSC	  differentiation.	   The	   differentiation	   capacity	   of	   most	   human	   progenitor	  populations	   has	   now	  been	   described	   at	   single	   cell	   resolution8–11.	   Furthermore,	  hHSC	  can	  now	  be	  purified	  to	  a	  level	  sufficient	  to	  make	  single	  cell	  transplantation	  possible	   12.	  A	  number	  of	  studies	  have	  applied	  genome-­‐wide	   techniques	   to	  start	  investigating	  the	  molecular	  circuits	  of	  human	  HSC	  and	  progenitor	  cells	  based	  on	  several	   purification	   strategies	   (Table	   1).	   Here	   we	   summarise	   what	   has	   been	  discovered	   about	   the	   molecular	   landscape	   of	   human	   HSC	   and	   their	   progeny.	  Finally	  we	  discuss	  how	  the	  normal	  HSC	  and	  progenitor	  molecular	  programs	  are	  subverted	  in	  leukaemia	  and	  in	  particular	  in	  Leukaemic	  Stem	  Cells	  (LSC),	  and	  how	  this	  information	  can	  be	  exploited	  for	  therapeutic	  purposes.	  	  	  
Transcriptional	   control	   of	   human	   haematopoietic	   stem	   cells	   and	   their	  
progeny	  
	  The	   transcriptional	  status	  of	  a	  cell	   is	  highly	  predictive	  of	   its	  cellular	   identity.	  A	  number	  of	  studies	  have	  thus	  aimed	  to	  derive	  transcriptional	  signatures	  of	  hHSC,	  isolated	   at	   different	   degrees	   of	   purity,	   by	   comparing	   their	   genome-­‐wide	  transcriptional	   profiles	   to	   those	   of	   their	   early	   progeny	   and/or	   more	  differentiated	   cells,	   either	   by	   microarray	   technology13–15	   or	   more	   recently	   by	  RNA-­‐seq16.	   All	   gene	   expression	   studies	   consistently	   found	   that	   hHSC	   isolated	  from	   cord	   blood	   have	   a	   distinct	   transcriptional	   programme	   compared	   to	   all	  mature	   haematopoietic	   cells,	   similar	   to	   mouse	   HSCs	   isolated	   from	   bone	  marrow17,18.	   Despite	   this	   clear	   dichotomy	   between	   HSC	   and	   progenitor	  transcriptional	   profiles,	   gene	   expression	   during	   haematopoiesis	   follows	   a	  modular	  architecture.	  Even	  though	  HSC	  programmes	  are	  drastically	  rearranged	  during	  differentiation,	  up	   to	  80	  common	  gene	  expression	  modules	  are	  used	  by	  distinct	  populations	  at	  different	  stages	  of	  differentiation13.	  	  	  Zooming	   in	   at	   high	   resolution	   on	   the	   very	   first	   steps	   of	   hHSC	   differentiation	  enables	   three	  main	  conclusions	  concerning	   their	  molecular	  make-­‐up.	  First,	   it	   is	  clear	  that	  HSCs	  have	  a	  unique	  transcriptional	  programme	  even	  when	  compared	  to	   lineage-­‐restricted	   progenitors	   (Figure	   1).	   Almost	   70%	   of	   the	   genes	  differentially	   expressed	   throughout	   early	   haematopoiesis	   are	   significantly	  changed	   upon	   exit	   from	   the	   HSC	   compartment15.	   Correspondingly,	   Gene	  Ontology	   analysis	   shows	   that	   almost	   all	   pathways	   and	   signalling	   cascades	   are	  significantly	  altered	  when	  HSCs	  differentiate.	  Functionally,	  this	  translates	  into	  a	  unique	   HSC	   metabolic	   programme5,	   but	   also	   distinct	   responses	   of	   HSC	   and	  progenitors	  to	  a	  number	  of	  external	  stimuli,	  including	  responses	  to	  stresses	  such	  as	  DNA	  damage19,20	  and	  unfolded	  protein	  response	  stress	  21,22.	  	  	  Second,	   in	   contrast	   to	   other	   progenitor	   cells	   that	   are	   transcriptionally	   distinct	  from	   hHSC	   such	   as	   common	   myeloid	   progenitors	   (CMP),	   myeloerythroid	  progenitors	   (MEP)	   and	   granulocyte-­‐macrophage	   progenitors	   (GMP),	  multilymphoid	   progenitors	   (MLP)	   share	  many	   transcriptional	   features	   of	   HSC.	  This	   similarity	   is	   particularly	   strong	   for	   transcription	   factor	   (TF)	   expression15	  suggesting	   that	   there	   is	   a	   common	  TF	  module	   that	  maintains	   self-­‐renewal	   and	  
differentiation	   potential.	   	   Loss	   of	   function	   studies	   of	   EBF1,	   or	   of	   transcription	  factors	   acting	   on	   the	   self-­‐sustaining	  EBF-­‐1/PAX5	   loop	   (IKZF,	   BCL11A,	   SOX4	  or	  TEAD1)	  have	  shown	  the	  context-­‐dependent	  effects	  of	  this	  circuitry:	  in	  MLP,	  these	  TF	   push	   differentiation	   towards	   the	   B	   cell	   lineage15,23	   whereas	   in	   HSCs	   they	  repress	  self-­‐renewal	  24,25.	  	  	  A	   third	   important	   finding	   regarding	   the	   transcriptional	   differences	   between	  functionally	  distinct	  subsets	  of	  hHSC	  is	  that	  human	  LT-­‐	  and	  ST-­‐HSC/MPP	  differ	  in	  their	   repopulation	   capacity	   and	   in	   their	   cell	   cycle	   properties.	   hLT-­‐HSC	   are	  capable	   of	   reconstituting	   a	   complete	   human	   haematopoietic	   system	   upon	  xenotransplantation,	  while	  hST-­‐HSC	  only	  produce	  transient	  grafts.	  Surprisingly,	  very	   few	   genes	   distinguish	   hLT-­‐HSC	   from	   hST-­‐HSC12,15,16,	  when	   these	   cells	   are	  isolated	  in	  a	  homeostatic	  quiescent	  state.	  One	  possibility	  may	  be	  that	  the	  distinct	  self-­‐renewal	   capacity	   of	   these	   HSC	   subsets	   is	   regulated	   as	   discussed	   below	   by	  long	   non-­‐coding	   RNA	   (lnc-­‐RNA),	   usage	   of	   alternative	   splicing	   events	   or	   post-­‐transcriptionally.	  While	  no	  proteomic	  analysis	  has	  been	  carried	  out	  at	  this	  level	  of	   resolution	   in	   human,	   Cabezas-­‐Wallscheid	   et	   al.	   found	   that	   only	   47	   proteins	  were	  differentially	  expressed	  between	  mouse	  HSC	  and	  multipotent	  progenitors	  26,	   suggesting	   that	   distinct	   hHSC	   subsets	   are	   also	   very	   likely	   to	   be	   extremely	  similar	   at	   the	   protein	   level.	   	   An	   alternative	   explanation	   may	   come	   from	   the	  quiescent	   state	   of	   these	   cells.	   Even	   though	   hLT-­‐	   and	   hST-­‐HSCs	   are	   equally	  quiescent	   under	   homeostatic	   conditions,	   their	   cell	   cycle	   behaviour	   is	   very	  different	  when	   they	  are	   challenged	   to	  divide27.	  Correspondingly	  hLT-­‐	  and	  hST-­‐HSCs	  diverge	  transcriptionally	  when	  cycling	  in	  vivo.	   	  When	  integrating	  the	  data	  at	  homeostasis	  and	  under	  activated	  cycling	  conditions,	  hLT-­‐	  and	  hST-­‐HSCs	  were	  found	  to	  differ	  in	  genes	  related	  to	  cell	  cycle,	  chromatin	  remodelling	  and	  immune	  response	   27,	   categories	   very	   similar	   to	   those	   reported	   to	   differ	   between	  equivalent	  mouse	  HSC	  subsets	  26.	  These	  data	  also	  show	  that	  cell	  cycle	  status	  not	  only	  plays	  an	  important	  role	  in	  defining	  the	  identity	  of	  functionally	  distinct	  HSC	  subsets,	   but	   also	   determines	   their	   transcriptional	   output.	   In	   mouse	   models,	  several	  studies	  have	  recently	  used	  single	  cell	  RNA-­‐seq	  to	  provide	  further	  insights	  into	   heterogeneity	   within	   the	   HSC	   pool	   28–30.	   In	   human,	   very	   little	   is	   known	  besides	   the	   characterization	   of	   HSC	   subsets	   based	   on	   CD90	   8,	   CD49f	   12	   or	   cKit	  
expression	   31.	   Future	   studies	   combining	   usage	   of	   novel	   cell	   surface	   markers,	  single	   cell	   transcriptomics	   and	   functional	   assays	   will	   help	   provide	   a	   more	  comprehensive	  understanding	  of	  hHSC	  heterogeneity.	  	  	  Even	  though	  all	  findings	  at	  the	  gene	  level	  are	  highly	  consistent	  between	  studies	  independent	  of	   the	   technology	  used	  15,16,	   the	  advent	  of	  RNA-­‐seq	  has	  uncovered	  several	  novel	   levels	  of	  HSC	  regulation.	  hHSC	  are	  characterised	  by	  high	   levels	  of	  non-­‐coding	   transcripts,	   in	   particular	   long	   non-­‐coding	   RNAs	   (lncRNAs),	   which	  change	  significantly	  during	  their	  differentiation16.	  More	  than	  a	  hundred	  lncRNAs	  are	  also	  enriched	  in	  mouse	  HSC	  26,32.	  In	  addition,	  Chen	  et	  al.16	  identified	  a	  number	  of	  novel	  splice	   junctions	  that	  are	  differentially	  used	   in	   the	  haematopoietic	   tree,	  and	   catalogued	   2301	   alternative	   splicing	   events	   that	   occur	   across	  haematopoiesis.	   Many	   of	   these	   lead	   to	   gain	   or	   loss	   of	   functional	   domains,	  suggesting	  that	  modulation	  of	  alternative	  splicing	  may	  play	  an	  important	  role	  to	  determine	   protein	   function	   during	   differentiation	   of	   haematopoietic	   cells.	  Importantly,	   both	   lncRNAs	   and	   splicing	   events	   are	   highly	   species-­‐specific	   and	  have	   been	   shown	   to	   fine	   tune	   expression	   and	   differentiation	   capacity	   in	   other	  stem	  cell	  systems	  33–35.	  Hence	  it	  will	  be	  interesting	  to	  verify	  to	  what	  extent	  this	  novel	   layer	  of	   regulation	  contributes	   to	   the	  subtle	  but	   important	  differences	   in	  HSC	  function	  observed	  between	  mice	  and	  humans36	  .	  	  	  	  While	  the	  studies	  discussed	  above	  used	  hHSC	  isolated	  from	  cord	  blood,	  because	  of	   its	   ease	  of	   access	   and	   abundance	   compared	   to	   adult	   haematopoietic	   organs,	  adult	  bone	  marrow	  hHSC	  and	  progenitor	  fractions	  gene	  expression	  profiles	  have	  also	   been	   generated	   10,14,37.	   	   No	   direct	   bioinformatic	   comparison	   of	   cord	   blood	  and	  bone	  marrow	  HSC	  has	  been	  reported	  to	  date.	  However,	  Pang	  et	  al.	  compared	  the	   gene	   expression	   profiles	   of	   hHSC	   isolated	   from	   young	   and	   elderly	   healthy	  donors	   and	   found	   that	   aged	   hHSC	   downregulate	   genes	   linked	   to	   lymphoid	  specification	  such	  as	  FLT3	  and	  SOX4,	  but	  also	  upregulate	  genes	  of	  the	  MAPK,	  G-­‐CSF	   and	   DNA	   repair	   pathways	   37,	   consistent	   with	   the	   myeloid-­‐bias	   37,38	   and	  increased	   replication	   stress	   observed	   in	   elderly	  HSC	   39.	   In	   summary,	   hHSC	   are	  characterized	  by	  unique	  molecular	  programmes	  that	  are	  driven	  by	  specific	  gene,	  
splicing	   isoform	   and	   lncRNA	   expression,	   which	   globally	   determine	   a	   unique	  stemness	  pathway	  and	  signalling	  phenotype	  (Figure	  1).	  	  	  	  
Epigenetic	  regulation	  of	  normal	  haematopoiesis	  	  Epigenetic	   regulation,	   via	   histone	  modification	   and	  DNA	  methylation,	   is	   key	   to	  determining	   cell	   fate	   in	   many	   systems16.	   	   While	   the	   understanding	   of	   the	  epigenetic	   mechanisms	   underpinning	   HSC	   regulation	   comes	   principally	   from	  studies	  with	  transgenic	  mouse	  models	  40,41,	  recently	  there	  have	  also	  been	  reports	  of	   how	   the	   epigenetic	   landscape	   changes	   when	   HSCs	   differentiate	   and	   upon	  aging.	   In	  mice,	   DNA	  methylation	   decreases	   on	   lineage-­‐specific	   gene-­‐regulatory	  elements	   as	   blood	   and	   skin	   stem	   cells	   differentiate	   40–42.	   In	   keeping	   with	   this	  finding,	   an	   array-­‐based	   method	   found	   that	   CB-­‐derived	   differentiated	   myeloid	  cells	  are	  globally	  hypomethylated	  at	  promoters	  compared	  to	  CD34+	  human	  stem	  and	  progenitor	  cells	  (HSPCs),	  also	  derived	  from	  CB	  43.	  During	  aging,	  global	  hypo-­‐methylation	  accompanied	  by	  de	  novo	  methylation	  at	  specific	  and	  restricted	  sites	  has	  been	  observed	  in	  many	  tissues.	  Accordingly,	  HSPCs	  isolated	  from	  mobilized	  peripheral	   blood	   of	   young	   adults,	   were	   less	   methylated	   than	   their	   CB	  counterparts,	   especially	   at	   differentiation	   genes,	   and	   also	   displayed	   some	  examples	  of	  de	  novo	  methylation.	  A	  much	  finer	  picture	  of	  changes	  in	  methylation	  with	  aging	  is	  derived	  from	  studies	  of	  mouse	  haematopoiesis.	  In	  contrast	  to	  other	  cell	   types,	   HSCs	   from	   old	   mice	   display	   higher	   levels	   of	   methylation	   at	   CpG	  islands40,44.	   However	   methylation	   changes	   are	   highly	   site-­‐specific:	   TF	   binding	  sites	   associated	   with	   lineage	   restriction	   are	   generally	   hypermethylated	  compared	   to	   young	   animals,	   while	   loci	   associated	   with	   HSC	   maintenance	   are	  hypomethylated44.	   De	   novo	   methylation	   occurs	   predominantly	   in	   genes	  associated	   with	   lineage	   specification	   in	   aged	   HSCs,	   but	   only	   changes	   their	  expression	   in	   their	   downstream	   progeny40.	   In	   addition	   the	   proportion	   of	   5-­‐hydroxymethycytosine	   (5hmC)	   in	   HSCs	   decreases	   with	   age	   44.	   	   It	   will	   be	  important	  to	  verify	  whether	  similar	  changes	  are	  happening	  in	  elderly	  humans.	  	  
Chromatin	  marks	  are	  also	  dynamically	  changed	  in	  haematopoiesis.	  In	  both	  mice	  and	  humans,	   the	  HSC	  compartment	  displays	  high	   levels	  of	  histone	  methylation	  (H3K4me3)	   that	   is	   lost	   at	  many	   bivalent	   loci	   upon	   differentiation44–46.	   Using	   a	  chromatin	   immunoprecipitation	   system	   optimized	   to	   analyse	   a	   few	   hundred	  cells,	   Lara-­‐Astasio	   et	   al.	   showed	   that	   during	   mouse	   haematopoiesis	   poised	  enhancers	   and	   open	   chromatin	   are	   established	   together	   mainly	   in	   progenitor	  cells	   to	   establish	   transcriptional	   programs	   that	   are	   only	   then	   executed	   in	  differentiated	   cells	   47.	   This	   makes	   progenitor	   cells,	   and	   not	   HSC,	   the	   most	  complex	   and	   dynamic	   populations	   in	   terms	   of	   chromatin	   modifications.	   As	  sequence	   changes	   in	   enhancers	   are	   among	   the	   major	   drivers	   of	   phenotypic	  evolution	   48,	   similar	   studies	   in	   humans	   will	   prove	   important	   to	   understand	  human	   blood	   formation	   both	   in	   normal	   and	   malignant	   contexts.	   	   Chromatin	  marks	  in	  haematopoietic	  cells	  also	  change	  with	  age:	  many	  bivalent	  domains	  are	  also	   lost	   in	   aged	   mouse	   HSC,	   but	   overall	   there	   is	   a	   gain	   due	   to	   addition	   of	  H3K27me3	  marks	   to	   regions	  uniquely	  marked	  by	  H3K4me3	   in	   young	  HSC	   44.	   ,	  While	  whole-­‐genome	  DNA	  and	  histone	  methylation	  analysis	  has	  not	  been	  carried	  out	   on	   highly	   purified	   human	   HSC	   of	   any	   age	   group,	   increased	   incidence	   of	  mutations	   in	   epigenetic	   regulators	   (DNMT3A,	   TET2,	   IDH1,	   IDH2)	   is	   seen	  with	  age	  in	  humans	  49–53.	  It	  is	  thus	  very	  likely	  that	  epigenetic	  marks	  are	  also	  globally	  altered	  with	  time	  in	  humans	  and	  may	  contribute	  to	  the	  decline	  in	  HSC	  function.	  	  	  	  
Perturbation	  of	  HSC	  programmes	  in	  Acute	  Myeloid	  Leukemia	  	  The	   cancer	   stem	   cell	   (CSC)	   model	   postulates	   that	   cancers	   are	   organised	  hierarchically	  with	  a	  subpopulation	  of	  CSCs	  at	  the	  apex,	  which	  have	  self-­‐renewal	  capacity	   and	   can	   perpetuate	   cancer	   cell	   differentiation	   and	   progression	   to	  relapse	  54.	  It	  is	  now	  widely	  accepted	  that	  this	  model	  is	  applicable	  to	  most	  types	  of	  leukaemia	   and	   some	   solid	   malignancies	   55,56.	   	   Similarly	   to	   the	   normal	  haematopoietic	  system,	  Leukemic	  Stem	  Cells	  (LSCs)	  are	  considered	  to	  reside	  at	  the	  apex	  of	  a	  hierarchy	  of	   leukemic	  blood	  cells	   that	  gradually	   lose	  self-­‐renewal	  capacity	  while	   becoming	  more	  differentiated	   and	   acquiring	   the	   abnormal	  blast	  phenotype.	   Relapsed	   disease	   is	   thought	   to	   be	   related	   to	   survival	   of	   some	   LSC	  
after	   induction	   chemotherapy,	   as	   LSC	   are	   thought	   to	   be	   quiescent	   and	   thus	  inherently	   resistant	   to	  most	   forms	  of	   chemotherapy	   56–58.	   In	   the	   last	   few	  years	  there	   has	   been	   a	   strong	   effort	   to	   identify	   the	   functional	   and	   molecular	  characteristics	   of	   LSCs	   that	   distinguish	   them	   from	   the	   bulk	   non-­‐LSC	   leukemic	  cells	  as	  well	  as	  comparing	  LSC	  with	  normal	  HSCs	  and	  progenitor	  cells,	  with	  the	  goal	  to	  develop	  therapies	  targeted	  to	  LSC	  eradication	  in	  the	  clinical	  setting.	  	  Here	  we	   summarise	   the	   findings	   from	   studies	   at	   the	   genome-­‐wide	   level	   in	   Acute	  Myeloid	  Leukaemia	  (AML).	  	  The	  hierarchal	   structure	  of	  AML	  and	   the	  characterization	  of	  AML	  LSCs,	  both	   in	  mouse	  models	   and	  human	  primary	   samples,	   represent	   one	   of	   the	   best	   studied	  CSC	  systems	  57,59.	  Several	  studies	  have	  highlighted	  a	  hierarchy	  within	  AML,	  with	  LSCs	  enriched	  in	  the	  CD34+CD38-­‐	  fraction,	  giving	  rise	  to	  CD34+CD38+	  leukemia	  progenitor	   cells,	   which	   further	   differentiate	   into	   CD34-­‐	   leukemic	   blasts	   10,54,57.	  This	  led	  to	  the	  idea	  that	  AML	  LSCs	  may	  be	  restricted	  to	  the	  CD34+	  compartment,	  however	  with	  improved	  xenograft	  assays	  and	  broader	  patient	  sample	  analysis,	  it	  is	  now	  clear	  that	  there	  is	  no	  unique	  cell	  surface	  marker	  based	  definition	  of	  LSC	  10,60.	   While	   the	   majority	   of	   AML	   cases	   are	   CD34+,	   a	   significant	   proportion	   of	  primary	   AMLs	   are	   CD34-­‐,	   with	   LSC	   activity	   shown	   to	   be	   present	   in	   both	   the	  CD34+	   and	  CD34-­‐	   compartments	   independently	   of	   CD34	   status	   61–63.	   	  Hence,	   a	  functional	  definition	  is	  more	  reliable	  for	  the	  identification	  of	  LSC	  populations	  in	  individual	   AML	   patients.	   This	   is	   most	   commonly	   achieved	   by	   testing	   LSCs’	  capacity	  to	  re-­‐establish	  disease	  in	  immunodeficient	  mice57.	  With	  this	  in	  mind,	  the	  relationship	  between	  normal	  hHSC	  and	  AML	  LSC	  has	  now	  been	   investigated	  at	  the	   transcriptional,	   proteomic	   and	   epigenetic	   level,	   with	   the	   goal	   being	   to	  capture	   a	   common	   LSC	   molecular	   state	   in	   AML	   independent	   of	   cell	   surface	  markers.	  	  A	   number	   of	   transcriptional	   signatures	   of	   AML	   LSCs	   have	   been	   defined	   in	   the	  past	   few	   years,	   with	   different	   experimental	   strategies	   (Table	   2).	   The	   first	   LSC	  signatures	   were	   established,	   comparing	   HSC	   and	   progenitor	   fractions	   isolated	  from	   healthy	   donors	   to	   the	   fractions	   with	   the	   same	   cell	   surface	   phenotype	   in	  AML	  patients	  14,64–66.	  In	  contrast,	  Eppert	  et	  al60	  defined	  LSC-­‐containing	  fractions	  
in	  16	  primary	  human	  adult	  AML	  samples	  using	  xenotransplantation.	  They	  then	  used	   bioinformatics	   to	   compare	   functionally	   defined	   LSC-­‐enriched	   fractions	   to	  fractions	  devoid	  of	  transplantation	  potential	  to	  derive	  an	  LSC-­‐specific	  signature.	  This	  LSC-­‐specific	   signature	  most	   closely	   resembles	   that	   of	   healthy	  HSCs	   rather	  than	   progenitor	   cells.	   In	   another	   study,	   Goardon	   et	   al.	   immunophenotypically	  defined	  the	  most	  expanded	  “normal”	  subpopulations	  and	  verified	  the	  presence	  of	  LSCs	   in	  100	  CD34+	  AML	  samples,	   the	  most	  abundant	   type	  of	  AML.	  They	   found	  that	  most	   samples	   contain	   an	  MPP-­‐like	   and	   GMP-­‐like	   LSC.	   In	  most	   cases	   both	  fractions	   from	  the	  same	  patient	  can	  engraft	   in	  xenografts.	  They	  then	  compared	  the	  gene	  expression	  profiles	  of	  each	  of	  these	  fractions	  from	  27	  AML	  patients	  to	  age-­‐matched	  normal	  HSC	  and	  progenitor	  compartments.	  They	   found	   that	   these	  LSC-­‐enriched	   AML	   expanded	   populations	   most	   closely	   resemble	   normal	  progenitor	  cells	  rather	  than	  HSCs	  when	  compared	  by	  gene	  expression	  profiling10.	  However,	   self-­‐renewal	   genes	   are	   enriched	   in	   these	   LSC	   fractions	   compared	   to	  normal	  progenitor	  cells,	  suggesting	  a	  strong	  HSC	  component.	  While	  these	  last	  2	  studies	   differ	   in	   the	   bioinformatics	   comparisons	   performed,	   the	   picture	   that	  emerges	   is	   one	  where	   LSC	   have	   hybrid	  molecular	   programs	   combining	   strong	  elements	  of	  HSC	  along	  with	  pathways	  typical	  of	  progenitors	  (Figure	  1).	  	  Interestingly,	   the	   similarity	   between	   HSC	   and	   LSC	   is	   also	   observed	   at	   the	  epigenetic	  level.	  In	  the	  MLL-­‐AF10	  induced	  AML	  mouse	  model,	  the	  LSC	  population	  has	   been	   well	   characterized	   phenotypically	   67	   and	   displays	   high	   H3K9me3	  methylation	   68,	   similar	   to	   HSC	   44–46.	   KDM5b-­‐driven	   demethylation	   induces	   LSC	  differentiation	   also	   in	   primary	   human	   AMLs	   68,	   demonstrating	   that	   dynamic	  changes	  in	  chromatin	  marks	  also	  regulate	  leukaemic	  hierarchies.	  	  	  	  No	  single	  cell	  transcriptomics	  are	  yet	  available	  on	  leukaemic	  blasts,	   let	  alone	  in	  LSC.	  	  However	  a	  high	  dimensional	  single	  cell	  proteomics	  and	  signalling	  approach	  was	   used	   by	   Levine	   et	   al.	   69	   to	   provide	   characterisation	   of	   intra-­‐	   and	   inter-­‐tumoural	   heterogeneity	   from	   31-­‐parameter	   mass	   cytometry	   data	   from	   16	  pediatric	   AML	   samples	   and	   5	   healthy	   adult	   donors.	   They	   found	   that	   the	   AML	  phenotype	   landscape	  can	  be	  described	  by	  14	  metaclusters,	  each	  with	  a	  specific	  surface	  marker	  pattern,	  reminiscent	  of	  that	  of	  normal	  myeloid	  development.	  It	  is	  
possible	  that	  this	  limited	  repertoire	  of	  states	  within	  these	  AML	  patients	  is	  likely	  to	   represent	   the	   limited	   heterogeneity	   that	   generally	   marks	   paediatric	  malignancies	   70.	   	   However	   no	   patient	   had	   a	   unique	   phenotype,	   but	   rather	   had	  distinct	  proportions	  of	  each	  of	  the	  metaclusters,	  in	  a	  way	  partially	  correlated	  to	  genetic	   factors.	  To	  estimate	   the	  extent	   to	  which	  elements	  of	  a	  stem/progenitor	  cell	   state	   are	   maintained	   in	   each	   AML,	   the	   authors	   used	   signalling	   responses	  after	   perturbation.	   They	   found	   that	   similarly	   to	   functional	   definition	   of	   HSC,	  signalling	  definition	   is	   correlated	  with	   cell	   surface	  markers	   in	   healthy	   samples	  but	  not	  in	  AML.	  This	  highlights	  that	  despite	  the	  very	  high	  degree	  of	  inter-­‐tumour	  heterogeneity,	   AML	   nonetheless	   maintains	   an	   architecture	   based	   on	   the	  reshuffling	   of	   the	   normal	  modules	   of	   normal	  myeloid	   development,	   and	   that	   a	  primitive	   stemness	   component	   is	   present	   in	   all	   AML	   to	   different	   degrees,	  regardless	  of	  surface	  marker	  expression	  and	  underlying	  genetic	  mutations.	  	  	  
Prognostic	  value	  of	  stem	  cell	  signatures	  in	  leukaemia	  	  Age,	   cytogenetics	   and	   molecular	   mutations	   are	   currently	   the	   most	   used	  predictors	  of	  outcome	  for	  AML,	  but	  evidence	   is	  accumulating	  that	  HSC	  and	  LSC	  signatures	  may	  have	  additional	  prognostic	  value	  compared	  to	  these	  parameters.	  A	  gene	  expression	  signature	  derived	  from	  transcriptional	  data	  by	  comparing	  HSC	  to	   phenotypically	   defined	   LSC14	   	   is	   predictive	   of	   primary	   refractoriness	   to	  chemotherapy,	  overall	   (OS),	  event-­‐free	  (EFS)	  and	  relapse-­‐free	  (RFS)	  survival	   in	  cytogenetically	   normal	   patients,	   and	   with	   OS	   in	   patients	   with	   chromosomal	  abnormalities.	  When	  comparing	  LSC	  to	  non-­‐LSC	  fractions	  defined	  functionally	  by	  their	   capacity	   to	   establish	   disease	   in	   the	   xenograft	   model,	   Eppert	   et	   al.	  established	  an	  LSC	  signature	  that	  can	  predict	  OS	  and	  EFS	  independently	  of	  other	  known	  prognostic	  factors	  such	  as	  age,	  low	  molecular	  risk	  and	  CEBPA	  mutational	  status	  60.	  An	  HSC	  signature	  derived	  by	  comparing	  normal	  HSC	  enriched	  fractions	  to	  progenitor	  fraction	  had	  similar	  prognostic	  value;	  gene	  set	  enrichment	  analysis	  shows	   a	   high	   enrichment	   of	   HSC	   genes	   within	   the	   LSC	   gene	   expression	   data	  explaining	   this	   result.	   In	   addition	   these	   signatures	   could	   further	   stratify	   low	  molecular	   risk	   patients	   according	   to	   their	   response	   to	   standard	   therapy,	   thus	  
allowing	   a	   priori	   identification	   of	   patients	   who	   could	   benefit	   from	   more	  aggressive	   clinical	   protocols.	   As	   multidimensional	   profiling	   of	   signalling	  responses	  can	  also	  unequivocally	  identify	  a	  stem	  cell	  or	  primitive	  state	  69,	  Levine	  et	  al.	  also	  generated	  a	  gene	  expression	  signature	  that	  can	  serve	  as	  a	  proxy	  for	  the	  primitive	   signalling	   phenotype.	   Interestingly	   this	   signature	   also	   very	   strongly	  correlated	  with	  poor	  survival	  in	  adult	  AML	  patients69.	  	  The	  question	  remains	  of	  what	  is	  the	  molecular	  driver	  of	  these	  signatures.	  Diffner	  et	  al.	   investigated	   if	   the	  heptad	  of	  TFs	  (ERG,	  FLI1,	  GATA2,	  LMO2,	  LYL1,	  RUNX1	  and	  SCL)	  forming	  a	  critical	  regulatory	  circuit	  in	  normal	  HSCs	  71,	  also	  plays	  a	  role	  in	   determining	   primitive	   expression	   signatures	   in	   AML	   72.	   Indeed	   signatures	  derived	   from	   both	   the	   expression	   of	   these	   7	   TFs	   and	   their	   activity	   at	  promoters/enhancers	   independently	   correlated	   with	   poor	   prognosis	   in	  cytogenetically	   normal	   AMLs	   72.	   	   The	   exact	   pattern	   of	   regulatory	   expression	  changes	   depending	   on	   the	  mutational	   status	   of	   the	   AML	   sample	   (NPM1	  wt	   or	  mutant),	  but	   these	  data	   indicate	   that	   the	  maintenance	  or	   re-­‐activation	  of	   these	  regulatory	  circuits	  in	  AML	  is	  largely	  responsible	  for	  the	  similarities	  between	  HSC	  and	  LSC.	  Beyond	  control	  by	  TF	  networks,	  there	  are	  several	  other	  possible	  factors	  contributing	  to	  leukaemic	  signatures.	  These	  may	  include	  the	  cell	  of	  origin,	  age	  of	  the	   patient	   (pediatric	   vs	   adult	   leukaemias),	   the	   tumour	   environment,	   and	  combinations	   of	   molecular	   mutations	   in	   the	   context	   of	   the	   constitutional	  germline	  genome	  of	  the	  patient.	  	  Interestingly,	   epigenetic	   signatures	   derived	   from	  AML	   genes	  with	   alteration	   of	  histone	   3	   lysine	   9	   trimethylation	   (H3K9me3)	   in	   combination	  with	   established	  clinical	   prognostic	   markers	   have	   also	   been	   shown	   to	   be	   more	   accurate	  prognostic	   factors	   than	   the	   clinical	   parameters	   alone	   73.	   Based	   on	   all	   of	   these	  findings,	   we	   speculate	   that	   any	   resemblance	   to	   a	   stem-­‐cell	   like	   state,	   at	   the	  transcriptional,	   proteomic,	   epigenetic	  or	   signalling	   level	  drives	  aggressive	  AML	  behaviour	  and	  influences	  clinical	  outcome.	  	  	  Finally,	   the	   advances	   in	   understanding	   the	   molecular	   programmes	   underlying	  healthy	  HSC	  differentiation	  have	  also	  proven	  useful	  to	  provide	  insights	   into	  the	  
intra-­‐	   and	   inter-­‐tumour	   heterogeneity	   of	   leukaemias	   other	   than	   AML.	   For	  example,	  a	  subpopulation	  with	  LSC	  characteristics	  has	  been	  shown	  to	  have	  gene	  signatures	   similar	   to	   that	   of	   HSCs	   in	   NPM-­‐ALK	   induced	   anaplastic	   large	   cell	  lymphoma	   (ALCL)	   74.	   In	   addition,	   the	   gene	   expression	   profile	   of	   early	   T	   cell	  precursor	   acute	   lymphoblastic	   leukaemia	   (ETP-­‐ALL),	   an	   aggressive	   paediatric	  and	   young	   adult	   malignancy,	   is	   highly	   correlated	   to	   that	   of	   normal	   human	  haematopoietic	   and	  myeloid	   stem	   cells,	   but	   also	   to	   the	   AML	   LSC	   signature	   60.	  These	  results	  suggest	  a	  potentially	  beneficial	  role	  of	  myeloid	  directed	  therapy	  in	  this	  disease	  75.	  	  	  
	  
	  
Conclusions	  and	  clinical	  implications	  Genome-­‐wide	   technologies	   have	   provided	   the	   first	   insights	   into	   the	  molecular	  architecture	  underlying	  blood	  formation.	  The	  picture	  that	  emerges	  is	  one	  where	  programmes	   operating	   in	   HSC	   are	   distinct	   from	   any	   other	   healthy	  haematopoietic	   cell;	   not	   only	   at	   the	   gene	   expression	   level	   but	   also	   through	  unique	  usage	  of	  splicing	  isoforms,	  enhancers,	  regulatory	  RNAs.	  Epigenetic	  marks	  are	  also	  highly	   remodelled	  during	  HSC	  differentiation.	  One	  of	   the	   challenges	  of	  collecting	  all	  this	  genome-­‐wide	  data	  is	  to	  understand	  its	  functional	  relevance	  on	  human	  HSC	  biology	  experimentally.	  Many	  of	  the	  hypotheses	  generated	  by	  these	  studies	   have	   allowed	   identification	   of	   novel	   molecular	   regulators	   of	   HSC	  function,	  when	  tested	  individually	  by	  gain	  or	  loss	  of	  function	  assays	  with	  in	  vitro	  or	  xenograft	  assays.	  There	  are	  certainly	  limitations	  to	  the	  current	  methodologies	  to	   test	   for	  hHSC	   function	  (rare	  populations,	   lack	  of	  a	  native	  microenvironment,	  relatively	  short-­‐term	  assays	  compared	  to	  human	  lifespan,	  failure	  to	  expand	  hHSC	  in	   culture…).	  To	  overcome	   these,	   a	  number	  of	  novel	  humanized	  mouse	  models	  are	   being	   developed	   76,77	   as	   well	   as	   approaches	   to	   generate	   hHSPCs	   from	  pluripotent	   cells	   78.	   These	   coupled	   to	   fast	   progress	   in	   single	   cell	   technologies,	  tissue	  engineering,	  genome	  editing	  and	  more	  extensive	  information	  from	  human	  genetics,	  should	  allow	  a	  better	  understanding	  of	  the	  regulation	  of	  hHSC	  function.	  	  In	  AML,	   LSC	  display	   a	   chimeric	   circuitry	   reflective	   of	   both	  HSC	   and	  progenitor	  cells,	  even	  though	  the	  exact	  HSC	  programme	  elements	  preserved	  vary	  between	  













Figure	   1:	   Schematic	   representation	   of	   the	   molecular	   programmes	   in	   the	  
healthy	  and	  leukaemic	  haematopoietic	  hierarchies.	  During	  healthy	  blood	   formation	  (left	  panel),	   the	  molecular	  programmes	  of	  HSC	  (top)	   are	   clearly	   distinct	   from	   those	   of	   progenitor	   (bottom)	   and	   differentiated	  cell	   types	   (not	   depicted).	   In	   contrast,	   in	   AML	   (right	   panel),	  where	   a	  malignant	  hierarchy	  is	  retained,	  LSCs	  are	  characterized	  by	  a	  chimeric	  reorganisation	  of	  HSC	  and	   progenitor	   programmes.	   Pathway	   here	   indicates	   a	   group	   of	   biological	  entities	   (mRNAs,	   miRNA,	   lnc-­‐RNAs…)	   that	   interact	   together	   in	   a	   cascade	   or	  network	  to	  regulate	  a	  particular	  cellular	  function.	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Table	  1:	  phenotypic	  definitions	  of	  HSC	  populations	  used	  in	  transcriptomics	  
and	  epigenetic	  studies.	  	  
Population	   Cell	  surface	  markers	   Technique	   Organ	  
HSPC	   Lin-­‐	  CD34+	   Methylation	  array	  39	   CB/mPB	  39	  
HSPC	   CD133+	   Histone	  methylation	  ChIP-­‐seq	  41	   mPB	  41	  
HSPC1	   Lin-­‐	  CD133+	  CD34dim	   Microarray	  13	   CB	  13	  
HSPC2	   Lin-­‐	  CD34+	  CD38-­‐	   Microarray	  13	   CB	  13	  
HSC	   Lin-­‐	  CD34+	  CD38-­‐	  CD90+	  CD45RA-­‐	   Microarray	  10,14,33	   CB/BM	  14	  BM	  10,33	  
MPP	   Lin-­‐	  CD34+	  CD38-­‐	  CD90-­‐	  CD45RA-­‐	   RNA-­‐seq	  16	   CB	  16	  
LT-­‐HSCs	   Lin-­‐	  CD34+	  CD38-­‐	  CD90+	  CD45RA-­‐	  CD49f+	   Microarray	  12,15,27	   CB	  12,15,27	  
ST-­‐HSCs	   Lin-­‐	  CD34+	  CD38-­‐	  CD90-­‐	  CD45RA-­‐	  CD49f-­‐	   Microarray	  12,15,27	   CB	  12,15,27	  	  	  
Table	  2:	  summary	  of	  studies	  reporting	  LSC	  signatures.	  	  
LSC	  definition	   Bioinformatic	  comparison	  	   	  Lin-­‐	  CD34+	  CD38-­‐	   LSC	  vs	  HSC	  61	  
Lin-­‐	  CD34+	  CD38-­‐	  CD123+	   LSC	  vs	  HSC	  60	  
















Pathway: A B C D E A B C D E
HSC transcriptional programme
DNA methylation
H3K4 methylation
Alternative splicing
mRNA
Alternative start
miRNAs
